Story
Peoples Bancorp Stock Drops on $728 Million All-Stock Deal for Capital Bancorp

Summary
Shares of Peoples Bancorp fell over 5% after the bank announced it would acquire Capital Bancorp in an all-stock transaction valued at approximately $728.1 million, raising investor concerns about share dilution.
Shares of Peoples Bancorp (PEBO) fell sharply in afternoon trading after the company announced an all-stock agreement to acquire Capital Bancorp (CBNK) for approximately $728.1 million. The market's negative reaction is typical for an acquirer in an all-stock deal, which dilutes the value of existing shares.
The Acquisition Details
Under the terms of the merger agreement, Capital Bancorp shareholders will receive 1.11 shares of Peoples common stock for each share of Capital common stock they own. Based on Peoples’ 20-day volume-weighted average price of $39.41 as of September 29, the transaction values Capital at $43.75 per share, according to the company's announcement.
The strategic goal of the acquisition is to increase scale and expand geographic presence. The combined entity is projected to have approximately $14 billion in total assets, $10 billion in loans, and $11 billion in deposits, with over 150 locations across eight states and Washington, D.C. The deal is expected to close in the first half of 2027, pending regulatory and shareholder approvals.
Market Reaction and Investor Concerns
AdFollowing the announcement, Peoples Bancorp's stock fell 5.5% to $36.72. This decline reflects the immediate impact of an all-stock transaction, where the issuance of new shares to fund the purchase dilutes the ownership stake of current shareholders and typically reduces tangible book value per share.
Adding to investor uncertainty, an investor rights law firm has reportedly launched an investigation into the merger. The firm is questioning whether Peoples and its board fulfilled their fiduciary duties to secure the best possible price for shareholders. This scrutiny, combined with the inherent execution risk of a large merger, contributed to the selling pressure.
Broader Context
While the broader market was mixed, with softer-than-expected inflation data providing a modest lift to the S&P 500 and Nasdaq, the company-specific news was the dominant driver for Peoples Bancorp. The stock's decline, one of its largest in the past year, underscores that investors view the merger as a significant event with near-term risks, including share dilution and a lengthy regulatory approval process.
Read next
More on Stocks
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.

Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.

Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.

Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.